Drug developers aiming to emulate the success of cancer targeted therapies and immunotherapy brands will struggle as a result of heightened competition and pharmacoeconomic constraints, suggests independent market analyst Datamonitor.
Over the last decade, the targeted therapies and immunotherapies class has fuelled growth in the oncology market, making it very attractive to drug developers aspiring to the commercial success of top brands such as Avastin (bevacizumab; Roche/Chugai), Rituxan (rituximab; Roche/Biogen Idec/Chugai/Zenyaku Kogyo), Herceptin (trastuzumab; Roche/Chugai) and Gleevec (imatinib; Novartis).
6.6% CAGR predicted, with sector reaching $37 billion
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze